<DOC>
	<DOCNO>NCT01940731</DOCNO>
	<brief_summary>1 . To evaluate clinical microbiological efficacy safety Colistimethate sodium Injection Vial treat adult hospital-acquired pneumonia . 2 . To Learn pharmacokinetic characteristic continuous intravenous infusion Colistimethate sodium .</brief_summary>
	<brief_title>Efficacy Safety Colistimethate Sodium Injection Vial Treat Hospital-acquired Pneumonia Adults</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>1 . Aged 1875 , either male female 2 . Women childbearing age negative pregnancy test time enrollment agree take effective contraceptive measure delivery 7 ~14 day stop . 3 . Defined hospitalacquired pneumonia follow criterion 4. fever , axillary temperature ≥37.3℃ , oral temperature≥37.8℃ , tympanic temperature≥38.2℃ , rectal temperature≥38.4℃ hypothermia rectal temperature &lt; 35℃ 5 . WBC &gt; 10000/μL &lt; 4000μL , neutrophil &gt; 70 % , rod neutrophil &gt; 10 % 6 . Pathogens highly suspect aerobic gramnegative bacillus . 7 . Before 72h admin agent , drug treatment use Systemic antibacterial activity gramnegative bacteria , le 48 hour . If 48h , must evidence clinic failure , eg . continue fever.WBC neutrophil irregular , respiratory secretions/blood bacterial culture positive . 8 . Informed consent grant . 1 . Pneumonia infect within 48h admission . 2 . Before 72h admin agent , drug treatment Systemic antibacterial activity 48 hour , unless clinical treatment failure . 3 . Patients know suspected single infection aerobic Grampositive cocci . 4 . Patients know single mixed infection Stenotrophomonas narrow food Aeromonas Burkholderia . 5 . Patients impaired consciousness . 6 . Patients primary pulmonary fibrosis , cystic fibrosis , lung cinerea pneumonia , active tuberculosis , Bronchial obstruction , history obstructive pneumonia ( mild severe COPD admission ) , primary lung cancer , tumor metastasis lung , bronchiectasis , lung abscess , empyema , noninfectious interstitial lung disease , pulmonary edema , atelectasis , pulmonary embolism , pulmonary eosinophil infiltration , pulmonary vasculitis , pleural effusion primary focus , aspiration pneumonia , fungal pneumonia atypical pathogen pneumonia . 7 . Patients bacterial infection lesion require antimicrobial drug therapy may hinder efficacy study drug evaluation . 8 . Glucocorticoids（eg , prednisone 20mg/d , treatment≥2 week） immunosuppressant used，or know HIV positive immunocompromised . 9 . Patients immediate evidence lifethreatening disease , include , limited , acute congestive heart failure , acute coronary syndrome , unstable arrhythmia . 10 . Patients sustainable shock make adequate fluid resuscitation ( systolic blood pressure &gt; 90mmHg ) 2h evidence hypoperfusion need sympathomimetic drug keep steady blood pressure . 11 . Patients severe neutropenia syndrome ( neutrophils &lt; 500 cells/mm3 ) expect suffer severe reduction neutrophil within 14days , take GGSF 48h study . 12 . Any patient endstage disease . 13 . Patients medical record multiple polymyxin anaphylactoid reaction . ( urticaria , angioedema , anaphylaxis , rash , scaling , etc . ) 14 . Patients Child Pugh C chronic liver disease , liver function abnormal . ( AST AST/ALT great 5 time upper limit normal , total bilirubin great 2 time upper limit normal ) 15 . Patients need major surgery 16 . Patients moderate severe renal impairment ( CrCL &gt; 50ml/min ) 17 . Patients take part clinical trial Colistimethate sodium。 18 . Patients take part drug instrument clinical trial . 19 . Pregnant , breastfeed keep breastfeed 20 . Patients involve planning operation study 21 . Patients poor compliance studyspecific procedure relate restriction . 22. disease may harmful patient quality data 23 . History epilepsy myasthenia gravis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>